Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Choosing anticancer drug targets in the postgenomic era.

The Journal of clinical investigation - 1 Dec 1999

Kaelin W G

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cell Division
Share to Drug Design
Share to Gene Targeting

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Genes, Tumor Suppressor

Share to Neoplasms

Share to Proto-Oncogene Proteins

Share to Retinoblastoma Protein

Source

Open in PubMed Open full text

Identifiers

PMID: 10587513
DOI: 10.1172/JCI8888
PMCID: PMC409873

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Choosing anticancer drug targets in the postgenomic era.PMID 10587513Read ↗

Genomics-guided pre-clinical development of cancer therapiesSemantic proximity Read ↗

Genomics and the second golden era of cancer drug developmentSemantic proximity Read ↗

Molecular-targeted anticancer therapy: challenges related to study design and choice of proper endpoints.Semantic proximity Read ↗

Understanding the Genetic Mechanisms of Cancer Drug Resistance Using Genomic ApproachesSemantic proximity Read ↗

Drug resistance: origins, evolution and characterization of genomic clones and the tumor ecosystem to optimize precise individualized therapySemantic proximity Read ↗

Machine learning in oncological pharmacogenomics: advancing personalized chemotherapySemantic proximity Read ↗

Designing drugs against heterogeneous targets.Semantic proximity Read ↗

Pharmacogenomics in Practice: Why Traditional Medicine Still LeadsSemantic proximity Read ↗

Achieving personalized cancer medicine: trials and tribulations.Semantic proximity Read ↗

Molecular determinants as therapeutic targets in cancer chemotherapy: An updateSemantic proximity Read ↗

Market watch: emerging companion diagnostics for cancer drugs.Semantic proximity Read ↗

Designing personalised cancer treatments.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.